Contribution of telacebec to novel drug regimens in a murine tuberculosis model
Antimicrobial Agents and Chemotherapy · 2025
DOI: 10.1128/aac.00962-24 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2025. Verfasst von Oliver D Komm und 10 weiteren Autor:innen. Beteiligte Einrichtung: Center for TB Research, Johns Hopkins University, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Antitubercular Agents, Mycobacterium tuberculosis, Mice, Inbred BALB C, Diarylquinolines. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The clinical efficacy of combination drug regimens containing the first-generation diarylquinoline (DARQ) bedaquiline in the treatment of multidrug-resistant tuberculosis has validated ATP synthesis as a vulnerable pathway in Mycobacterium tuberculosis . New DARQs in clinical development may be even more effective than bedaquiline, including against emerging bedaquiline-resistant strains. Telacebec (T) is a novel cytochrome bc 1 :aa 3 oxidase inhibitor that also inhibits ATP synthesis. Based on its demonstrated efficacy as a monotherapy in mice and in a phase 2a clinical trial, we tested the contribution of T to novel combination therapies against two strains of M. tuberculosis (H37Rv and HN878) in an established BALB/c mouse model of tuberculosis in an effort to find more effective regimens. Overall, T was more effective in regimens against the HN878 strain than against the H37Rv strain, a finding supported by the greater vulnerability of the former strain to T and to genetic depletion of QcrB. Against both strains, combinations of a DARQ, clofazimine, and T were highly bactericidal. However, only against HN878 did T contribute synergistically, whereas an antagonistic effect was observed against H37Rv. These results demonstrate the therapeutic potential of T and highlight how differences in the susceptibility of M. tuberculosis strains could lead to different conclusions about a drug’s potential contribution to novel drug regimens. CLINICAL TRIALS This study is registered with Clinicaltrials.gov as NCT04890535 and NCT06058299 .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for TB Research, Johns Hopkins University, Baltimore, Maryland, USA.
- TB Alliance, New York, New York, USA.
ORCID-Profile: Eric L Nuermberger
Zitieren
APA
Komm, O. D., Tyagi, S., Garcia, A., Almeida, D., Chang, Y., Li, S. Y., Castillo, J. R., Converse, P. J., Black, T., Fotouhi, N., & Nuermberger, E. L. (2025). Contribution of telacebec to novel drug regimens in a murine tuberculosis model. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00962-24
Vancouver
Komm OD, Tyagi S, Garcia A, Almeida D, Chang Y, Li SY, et al. Contribution of telacebec to novel drug regimens in a murine tuberculosis model. Antimicrobial Agents and Chemotherapy. 2025. doi:10.1128/aac.00962-24
BibTeX
@article{Komm2025,
author = {Komm, Oliver D and Tyagi, Sandeep and Garcia, Andrew and Almeida, Deepak and Chang, Yong and Li, Si-Yang and Castillo, Jennie Ruelas and Converse, Paul J and Black, Todd and Fotouhi, Nader and Nuermberger, Eric L},
title = {Contribution of telacebec to novel drug regimens in a murine tuberculosis model},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2025},
doi = {10.1128/aac.00962-24}
}
EUVIMED